Table Graph
      published meta-analysis   sensitivity analysis   studies

anticoagulant in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCOVID-PACT, 2022 0.91 [0.56; 1.48] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38] 1.04[0.84; 1.30]COVID-PACT, 2022, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202120%1,480moderatenot evaluable clinical improvementdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03] 0.83[0.67; 1.03]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202110%1,074NAnot evaluable Major thrombotic events or deathdetailed resultsCOVID-PACT, 2022 0.56 [0.32; 0.98] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36] 0.80[0.44; 1.46]COVID-PACT, 2022, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021273%1,473moderatenot evaluable Major bleedingdetailed resultsCOVID-PACT, 2022 3.86 [0.44; 34.07] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98] 1.62[0.83; 3.15]COVID-PACT, 2022, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202120%1,473moderatenot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-04-26 14:04 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 608,830,831,829,901,680,595,828,681,1209,833 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons